Melanotan 2

A non-selective melanocortin analog studied for pigmentation and central effects, without pharmaceutical approval

Overview

Melanotan 2 (MT-II) is a cyclic synthetic peptide developed as an analog of α-MSH. Unlike afamelanotide (Melanotan 1), it is a less selective agonist of the melanocortin system and can act on several receptors, not only MC1R in the skin [1,2]. Early studies in the 1990s showed that it is able to increase pigmentation in humans [1]. Central effects on libido and erection were later identified as well, which led to the development of other molecules from the same receptor family [2,3]. Melanotan 2 is not approved by the FDA for tanning or for any other therapeutic indication. The FDA notes significant safety concerns regarding compounded products containing it, including case reports of serious adverse events [4].

Biological Mechanism

The melanocortin system includes several receptors from the GPCR family. Activation of MC1R in melanocytes increases cAMP and eumelanin production, and can therefore lead to skin darkening. Melanotan 2 is not restricted to MC1R and can also activate melanocortin receptors in the central nervous system [2]. This broader activity explains why early experiments observed not only changes in pigmentation but also nausea, yawning, changes in libido and erectile responses [2,3]. In other words, the same non-selectivity that broadens the biological activity also increases the complexity of the side-effect profile. MT-II should therefore not be regarded as a 'color peptide' that acts only in the skin. It is a substance with systemic activity across different melanocortin pathways.

Research Evidence

An early 1996 study tested MT-II in humans and showed increased pigmentation after a series of experimental exposures [1]. Additional small studies examined its effect in men with erectile dysfunction and demonstrated an erectile response and increased libido in some participants [2,3]. These studies are important for demonstrating pharmacological activity, but they do not constitute a basis for cosmetic or medical approval. They were small, relatively old, and do not provide long-term information on repeated use in a broad population. The later literature consists mainly of observational studies, user reports and case reports of side effects. This is a weaker evidence base for assessing benefit, but it is important for identifying safety signals.

Pigmentation vs. Central Effects

The difference between Melanotan 1 and Melanotan 2 is not only in the name. Afamelanotide was developed around MC1R activity and received specific medical approval for EPP, whereas MT-II activates several receptors and shows more central effects [2]. As a result, changes in pigmentation can appear alongside effects that are not directly related to the skin. In early studies nausea and yawning were common, and in erection studies sexual activity was observed that was not necessarily dependent on ordinary sexual stimulation [2,3]. The multi-system profile is the reason why a safety assessment of MT-II requires more than monitoring skin color alone.

Safety & Regulation

The FDA includes Melanotan II in its list of substances that may present significant safety risks in the context of compounding. The agency notes concerns regarding immunogenicity and peptide-related impurities, as well as case reports of serious adverse events, including priapism, sympathomimetic syndrome, posterior reversible encephalopathy syndrome and melanoma [4]. It is important to emphasize that a case report does not necessarily prove that the peptide caused the event. For example, cases have been published in which melanoma appeared after use of MT-II, but there were sometimes other risk factors as well, such as intensive UV exposure [5]. The causal link to melanoma is therefore not proven at the level of a controlled trial. Nevertheless, the mere appearance of serious safety signals, combined with the absence of large, long-term safety studies, creates significant uncertainty. Changes in moles or pigmented lesions can also make proper skin monitoring more difficult.

Case Reports, Causality & Material Quality

Case reports are suitable for identifying rare effects, but they do not allow incidence to be calculated or causality to be proven. A case of priapism after MT-II, for example, is consistent with the central melanocortin mechanism known from the early studies, and is therefore considered a plausible biological signal [6]. By contrast, the question of melanoma risk is more complex and requires long-term epidemiological studies. In addition to the mechanism itself, unapproved products raise questions of chemical identity, purity, sterility and degradation products. When a substance is not manufactured as an approved pharmaceutical product, this uncertainty becomes part of the risk profile and cannot be separated from the evaluation of the peptide.

Summary

Melanotan 2 is a cyclic α-MSH analog acting on melanocortin receptors. Early studies examined its effect on pigmentation but did not establish an approved medical or cosmetic use [1-3], and the FDA notes significant concerns about the safety and quality of MT-II-containing products, including case reports of serious events [4-6]. It is an unapproved substance intended for laboratory research only and not for human use.

Selected Research Sources

1. Dorr R.T. et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. PMID: 8637402
2. Wessells H. et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research, 2000. PMID: 11035391
3. Wessells H. et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology, 1998. PMID: 9679884
4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Entry for Melanotan II.
5. Hjuler K.F. et al. Melanoma associated with the use of Melanotan-II. Dermatology, 2014. PMID: 24355990
6. Dreyer B.A. et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports, 2019. PMID: 30796078